459 related articles for article (PubMed ID: 24825494)
1. Mucoadhesive glycol chitosan nanoparticles for intranasal delivery of hepatitis B vaccine: enhancement of mucosal and systemic immune response.
Pawar D; Jaganathan KS
Drug Deliv; 2016; 23(1):185-94. PubMed ID: 24825494
[TBL] [Abstract][Full Text] [Related]
2. Development and characterization of surface modified PLGA nanoparticles for nasal vaccine delivery: effect of mucoadhesive coating on antigen uptake and immune adjuvant activity.
Pawar D; Mangal S; Goswami R; Jaganathan KS
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):550-9. PubMed ID: 23831265
[TBL] [Abstract][Full Text] [Related]
3. Strong systemic and mucosal immune responses to surface-modified PLGA microspheres containing recombinant hepatitis B antigen administered intranasally.
Jaganathan KS; Vyas SP
Vaccine; 2006 May; 24(19):4201-11. PubMed ID: 16446012
[TBL] [Abstract][Full Text] [Related]
4. Pharmaceutical and immunological evaluation of mucoadhesive nanoparticles based delivery system(s) administered intranasally.
Mangal S; Pawar D; Garg NK; Jain AK; Vyas SP; Rao DS; Jaganathan KS
Vaccine; 2011 Jul; 29(31):4953-62. PubMed ID: 21575664
[TBL] [Abstract][Full Text] [Related]
5. Immune response by nasal delivery of hepatitis B surface antigen and codelivery of a CpG ODN in alginate coated chitosan nanoparticles.
Borges O; Cordeiro-da-Silva A; Tavares J; Santarém N; de Sousa A; Borchard G; Junginger HE
Eur J Pharm Biopharm; 2008 Jun; 69(2):405-16. PubMed ID: 18364251
[TBL] [Abstract][Full Text] [Related]
6. Development and characterization of chitosan coated poly-(ɛ-caprolactone) nanoparticulate system for effective immunization against influenza.
Gupta NK; Tomar P; Sharma V; Dixit VK
Vaccine; 2011 Nov; 29(48):9026-37. PubMed ID: 21939718
[TBL] [Abstract][Full Text] [Related]
7. Development of a novel adjuvanted nasal vaccine: C48/80 associated with chitosan nanoparticles as a path to enhance mucosal immunity.
Bento D; Staats HF; Gonçalves T; Borges O
Eur J Pharm Biopharm; 2015 Jun; 93():149-64. PubMed ID: 25818119
[TBL] [Abstract][Full Text] [Related]
8. Hepatitis B surface antigen nanoparticles coated with chitosan and trimethyl chitosan: Impact of formulation on physicochemical and immunological characteristics.
Tafaghodi M; Saluja V; Kersten GF; Kraan H; Slütter B; Amorij JP; Jiskoot W
Vaccine; 2012 Aug; 30(36):5341-8. PubMed ID: 22749834
[TBL] [Abstract][Full Text] [Related]
9. Alginate coated chitosan nanoparticles are an effective subcutaneous adjuvant for hepatitis B surface antigen.
Borges O; Silva M; de Sousa A; Borchard G; Junginger HE; Cordeiro-da-Silva A
Int Immunopharmacol; 2008 Dec; 8(13-14):1773-80. PubMed ID: 18801462
[TBL] [Abstract][Full Text] [Related]
10. Immune response elicited by an intranasally delivered HBsAg low-dose adsorbed to poly-ε-caprolactone based nanoparticles.
Jesus S; Soares E; Costa J; Borchard G; Borges O
Int J Pharm; 2016 May; 504(1-2):59-69. PubMed ID: 26976502
[TBL] [Abstract][Full Text] [Related]
11. N,N,N-Trimethyl chitosan nanoparticles for controlled intranasal delivery of HBV surface antigen.
Subbiah R; Ramalingam P; Ramasundaram S; Kim DY; Park K; Ramasamy MK; Choi KJ
Carbohydr Polym; 2012 Aug; 89(4):1289-97. PubMed ID: 24750944
[TBL] [Abstract][Full Text] [Related]
12. Mono-N-carboxymethyl chitosan (MCC) and N-trimethyl chitosan (TMC) nanoparticles for non-invasive vaccine delivery.
Sayin B; Somavarapu S; Li XW; Thanou M; Sesardic D; Alpar HO; Senel S
Int J Pharm; 2008 Nov; 363(1-2):139-48. PubMed ID: 18662762
[TBL] [Abstract][Full Text] [Related]
13. Intranasal Administration of Novel Chitosan Nanoparticle/DNA Complexes Induces Antibody Response to Hepatitis B Surface Antigen in Mice.
Lebre F; Borchard G; Faneca H; Pedroso de Lima MC; Borges O
Mol Pharm; 2016 Feb; 13(2):472-82. PubMed ID: 26651533
[TBL] [Abstract][Full Text] [Related]
14. Poly-ϵ-caprolactone/chitosan nanoparticles provide strong adjuvant effect for hepatitis B antigen.
Jesus S; Soares E; Borchard G; Borges O
Nanomedicine (Lond); 2017 Oct; 12(19):2335-2348. PubMed ID: 28868964
[TBL] [Abstract][Full Text] [Related]
15. Immunoadjuvant potential of cross-linked dextran microspheres mixed with chitosan nanospheres encapsulated with tetanus toxoid.
Pirouzmand H; Khameneh B; Tafaghodi M
Pharm Biol; 2017 Dec; 55(1):212-217. PubMed ID: 27927058
[TBL] [Abstract][Full Text] [Related]
16. Plasmid DNA loaded chitosan nanoparticles for nasal mucosal immunization against hepatitis B.
Khatri K; Goyal AK; Gupta PN; Mishra N; Vyas SP
Int J Pharm; 2008 Apr; 354(1-2):235-41. PubMed ID: 18182259
[TBL] [Abstract][Full Text] [Related]
17. Single dose HBsAg CS-γ-PGA nanogels induce potent protective immune responses against HBV infection.
Wang H; Han Q; Zhao H; Xu D; Zhang J
Eur J Pharm Biopharm; 2018 Mar; 124():82-88. PubMed ID: 29247691
[TBL] [Abstract][Full Text] [Related]
18. Lipopolysaccharide derived alginate coated Hepatitis B antigen loaded chitosan nanoparticles for oral mucosal immunization.
Saraf S; Jain S; Sahoo RN; Mallick S
Int J Biol Macromol; 2020 Jul; 154():466-476. PubMed ID: 32194106
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of ISCOM vaccines for mucosal immunization against hepatitis B.
Pandey RS; Dixit VK
J Drug Target; 2010 May; 18(4):282-91. PubMed ID: 19958131
[TBL] [Abstract][Full Text] [Related]
20. Chitosan:β-glucan particles as a new adjuvant for the hepatitis B antigen.
Soares E; Jesus S; Borges O
Eur J Pharm Biopharm; 2018 Oct; 131():33-43. PubMed ID: 30048745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
